The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Estimated Growth In Market Size Of The Cosentyx Drug Market During 2026–2030?
The Cosentyx drug market has demonstrated strong growth in recent years. It is projected to increase from $5.68 million in 2025 to $6.21 million in 2026, reflecting a compound annual growth rate (CAGR) of 9.2%. This historical growth is attributable to several factors including the approval of IL 17 inhibitors, the high prevalence of psoriasis and arthritis, the limited efficacy of TNF inhibitors, the uptake by specialist dermatology, and the established biologic treatment guidelines.
The cosentyx drug market size is anticipated to experience robust growth over the next few years, expanding to $8.74 million by 2030 with a compound annual growth rate (CAGR) of 8.9%. This projected growth within the forecast period is driven by factors such as an increase in autoimmune disease diagnoses, an expansion of treatment indications, rising patient awareness, improved biologic accessibility, and support from long-term efficacy data. Prominent trends for the forecast period include the growing adoption of IL-17 inhibitor therapies, a broadening of use across various autoimmune indications, a transition towards targeted biologic treatments, increased application of long-term maintenance therapy, and a surging demand for self-injectable biologics.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19891&type=smp
Which Growth Drivers Are Expected To Support The Cosentyx Drug Market Forward?
The increasing occurrence of autoimmune diseases is projected to stimulate the expansion of the cosentyx market moving forward. Autoimmune diseases are disorders where the immune system mistakenly attacks the body’s own healthy cells and tissues. The growing prevalence of these conditions is linked to genetic predispositions, environmental elements (such as infections and pollutants), and changes in lifestyle, including heightened stress and dietary shifts. Cosentyx (secukinumab) assists autoimmune disease patients by targeting and inhibiting interleukin-17A, a key cytokine involved in the inflammatory process, thereby alleviating symptoms, enhancing quality of life, and effectively managing conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. For instance, in August 2024, data from Public Health Scotland, a national organization based in Scotland, revealed that in 2023, the Scottish Multiple Sclerosis Register (SMSR) recorded 455 newly diagnosed MS patients. This demonstrates how the rising prevalence of autoimmune diseases is propelling the cosentyx market.
How Is The Cosentyx Drug Market Examined Through Segment Analysis?
The cosentyx drug market covered in this report is segmented –
1) By Indication: Hidradenitis suppurativa, Psoriatic arthritis, Ankylosing spondylitis, Plaque Psoriasis
2) By Route Of Administration: Subcutaneous injection, Intravenous infusion
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Which Trends Are Shaping The Cosentyx Drug Market Landscape?
Key companies within the Cosentyx drug market are directing their efforts towards the creation of advanced therapies, including biological treatment alternatives, aiming to satisfy unmet medical requirements, improve the effectiveness of treatments, and offer focused therapies for managing chronic autoimmune conditions. This strategic focus enhances their market position and serves an expanding patient demographic. Biologic treatments are sophisticated therapies derived from living organisms or their cells, specifically engineered to target immune system components like interleukin-17A, thereby modulating inflammatory responses and providing effective treatment for autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. For example, in October 2023, Novartis AG, a pharmaceutical firm based in Switzerland, secured FDA approval for Cosentyx (secukinumab), making it the inaugural new biologic treatment option for moderate to severe hidradenitis suppurativa (HS) in nearly a decade. This endorsement represents a substantial progression in the treatment landscape for HS, a chronic and often debilitating skin condition characterized by painful nodules that can result in scarring and psychological distress.
Which Organizations Are Involved In The Cosentyx Drug Market?
Major companies operating in the cosentyx drug market are Novartis AG
Access The Complete Cosentyx Drug Market Report:
https://www.thebusinessresearchcompany.com/report/cosentyx-drug-global-market-report
Which Region Accounts For The Highest Share Of The Cosentyx Drug Market?
North America was the largest region in the cosentyx drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cosentyx drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model